Navigation Links
RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell

MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will ring the NASDAQ Stock Market closing bell on Friday, August 8, 2014. A live webcast will be available at

Logo -

"Listing on NASDAQ has allowed us to gain access to a broader institutional investment community," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Commemorating this accomplishment, by ringing the NASDAQ closing bell, is a good reminder of the progress we have already achieved with developing our self-delivering RNAi-based (sd-rxRNA®) technology platform into commercially viable assets.  We would like to thank our shareholders, patients, volunteers and advisors for their support in the Company's development."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, a self-delivering RNAi compound (sd-rxRNA®), entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal scars (fibrosis).  RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin.  RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks and uncertainties:  the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

RXi Pharmaceuticals Corporation
Tamara McGrillen

SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
2. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
3. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
4. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
5. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
6. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
7. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
8. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
9. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
10. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
11. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
Post Your Comments:
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has ... Prix, to represent the First–Person View (FPV) racing community. , FPV racing has exploded ... of racing and several new model aviation pilots have joined the community because of ...
(Date:11/24/2015)... Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that ... 2015 at 11:00 a.m. Israel time, at the ... Yigal Allon Street, 36 th Floor, Tel Aviv, Israel ... Paneth and Izhak Tamir to the Board of Directors; ... external directors; , approval of an amendment to certain terms of ...
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... LAVAL, QC , Nov. 24, 2015 /CNW Telbec/ - ... the "Corporation") announced today that Mr. Pierre Laurin , ... a corporate presentation at the upcoming Piper Jaffray 27 th ... York Palace Hotel, on December 1-2, 2015. ... be available for one-on-one meetings throughout the day. The presentation ...
Breaking Biology Technology:
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., a ... to mobile and PC devices, announced its ActiveIRIS® technology ... arrows NX F-02H launched by NTT DOCOMO, INC in ... is the second smartphone to include iris recognition technology, ... ARROWS NX F-04G in May 2015, world,s first smartphone ...
(Date:10/22/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... 30, 2015.  --> --> ... decrease of 33% compared to $6.0 million in the same quarter ... $2.2 million, or $0.10 per diluted share, which compared to $2.6 ... year ago.  --> --> ...
Breaking Biology News(10 mins):